More recently, there have been several reports that cancer patients with 1/10 tumor cells expressed PD-L1 and PD-L1 have worse outcomes (shorter recurrence-free survival (RFS) and OS following immunotherapy) (Lei et al., 2020). This evidence concerns the gene CD274 and neoplasm.